Michelle Ulrich
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Michelle Ulrich has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
- Shyra J. Gardai
EpiBiologics, San Mateo, California
28 shared publications - Weiping Zeng
Pfizer, Inc., Bothell, Washington
27 shared publications - Robert Thurman
Seagen Inc., Bothell, Washington
22 shared publications - Che-Leung Law
Harpoon Therapeutics, South San Francisco, California
20 shared publications - Martha E. Anderson
Seagen Inc., Bothell, Washington
20 shared publications - Mechthild Jonas
Seagen Inc., Bothell, Washington
20 shared publications
Latest Publications
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from Targeted Delivery of a Potent STING Agonist Payload via an Antibody–Drug Conjugate Drives Robust Antitumor Activity in Preclinical Models
Supplementary Figure 5 from Targeted Delivery of a Potent STING Agonist Payload via an Antibody–Drug Conjugate Drives Robust Antitumor Activity in Preclinical Models
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from Targeted Delivery of a Potent STING Agonist Payload via an Antibody–Drug Conjugate Drives Robust Antitumor Activity in Preclinical Models
Supplementary Figure 5 from Targeted Delivery of a Potent STING Agonist Payload via an Antibody–Drug Conjugate Drives Robust Antitumor Activity in Preclinical Models
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Targeted Delivery of a Potent STING Agonist Payload via an Antibody–Drug Conjugate Drives Robust Antitumor Activity in Preclinical Models
Supplementary Figure 4 from Targeted Delivery of a Potent STING Agonist Payload via an Antibody–Drug Conjugate Drives Robust Antitumor Activity in Preclinical Models
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Targeted Delivery of a Potent STING Agonist Payload via an Antibody–Drug Conjugate Drives Robust Antitumor Activity in Preclinical Models
Supplementary Figure 4 from Targeted Delivery of a Potent STING Agonist Payload via an Antibody–Drug Conjugate Drives Robust Antitumor Activity in Preclinical Models
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Targeted Delivery of a Potent STING Agonist Payload via an Antibody–Drug Conjugate Drives Robust Antitumor Activity in Preclinical Models
Supplementary Figure 2 from Targeted Delivery of a Potent STING Agonist Payload via an Antibody–Drug Conjugate Drives Robust Antitumor Activity in Preclinical Models
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Targeted Delivery of a Potent STING Agonist Payload via an Antibody–Drug Conjugate Drives Robust Antitumor Activity in Preclinical Models
Supplementary Figure 2 from Targeted Delivery of a Potent STING Agonist Payload via an Antibody–Drug Conjugate Drives Robust Antitumor Activity in Preclinical Models
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Targeted Delivery of a Potent STING Agonist Payload via an Antibody–Drug Conjugate Drives Robust Antitumor Activity in Preclinical Models
Supplementary Figure 1 from Targeted Delivery of a Potent STING Agonist Payload via an Antibody–Drug Conjugate Drives Robust Antitumor Activity in Preclinical Models
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Targeted Delivery of a Potent STING Agonist Payload via an Antibody–Drug Conjugate Drives Robust Antitumor Activity in Preclinical Models
Supplementary Figure 1 from Targeted Delivery of a Potent STING Agonist Payload via an Antibody–Drug Conjugate Drives Robust Antitumor Activity in Preclinical Models
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Targeted Delivery of a Potent STING Agonist Payload via an Antibody–Drug Conjugate Drives Robust Antitumor Activity in Preclinical Models
Supplementary Figure 3 from Targeted Delivery of a Potent STING Agonist Payload via an Antibody–Drug Conjugate Drives Robust Antitumor Activity in Preclinical Models
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Targeted Delivery of a Potent STING Agonist Payload via an Antibody–Drug Conjugate Drives Robust Antitumor Activity in Preclinical Models
Supplementary Figure 3 from Targeted Delivery of a Potent STING Agonist Payload via an Antibody–Drug Conjugate Drives Robust Antitumor Activity in Preclinical Models
- Open Access
- 29 October 2025
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 25 (3) , 457-468
Targeted Delivery of a Potent STING Agonist Payload via an Antibody–Drug Conjugate Drives Robust Antitumor Activity in Preclinical Models
Stimulator of IFN genes (STING) is an innate immune pathway that activates a type I IFN response upon detection of intracellular DNA from foreign pathogens as well as tumor cells. STING signaling is critical for antiviral immunity and can be co-opted to drive an antitumor immune response. However, STING activation requires careful and controlled agonism to drive immune activation in the tumor microenvironment (TME) while avoiding toxic systemic immune activation. Indeed, nontargeted small-molecule STING agonist therapeutics have shown limited antitumor activity in the clinic, likely due to their short half-life and poor retention within the TME. We hypothesized that targeted delivery of a potent STING agonist payload directly to the TME via an antibody–drug conjugate (ADC) may overcome some of these limitations. In this study, we report the development of a novel STING agonist ADC with a noncleavable linker-payload (ncSTING). Tumor-targeted ADCs employing this linker-payload (ncSTING ADC) elicited robust antitumor activity in a variety of preclinical murine tumor models. We found that Fcγ receptor binding affected antitumor activity as ADCs with a wild-type Fc drove more antitumor activity than ADCs with an Fcγ receptor-binding mutant Fc in a subset of tumor models. Moreover, tumor-targeted ncSTING ADCs elicited tumor regression with reduced systemic immune activation compared with the systemic administration of the released payload. Altogether, these data provide a therapeutic rationale for the targeted delivery of a potent STING agonist payload via an ADC.
- 29 October 2025
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 25 (3) , 457-468
Open AccessTargeted Delivery of a Potent STING Agonist Payload via an Antibody–Drug Conjugate Drives Robust Antitumor Activity in Preclinical Models
Stimulator of IFN genes (STING) is an innate immune pathway that activates a type I IFN response upon detection of intracellular DNA from foreign pathogens as well as tumor cells. STING signaling is critical for antiviral immunity and can be co-opted to drive an antitumor immune response. However, STING activation requires careful and controlled agonism to drive immune activation in the tumor microenvironment (TME) while avoiding toxic systemic immune activation. Indeed, nontargeted small-molecule STING agonist therapeutics have shown limited antitumor activity in the clinic, likely due to their short half-life and poor retention within the TME. We hypothesized that targeted delivery of a potent STING agonist payload directly to the TME via an antibody–drug conjugate (ADC) may overcome some of these limitations. In this study, we report the development of a novel STING agonist ADC with a noncleavable linker-payload (ncSTING). Tumor-targeted ADCs employing this linker-payload (ncSTING ADC) elicited robust antitumor activity in a variety of preclinical murine tumor models. We found that Fcγ receptor binding affected antitumor activity as ADCs with a wild-type Fc drove more antitumor activity than ADCs with an Fcγ receptor-binding mutant Fc in a subset of tumor models. Moreover, tumor-targeted ncSTING ADCs elicited tumor regression with reduced systemic immune activation compared with the systemic administration of the released payload. Altogether, these data provide a therapeutic rationale for the targeted delivery of a potent STING agonist payload via an ADC.
- Open Access
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Figure S4 from Brentuximab Vedotin–Driven Microtubule Disruption Results in Endoplasmic Reticulum Stress Leading to Immunogenic Cell Death and Antitumor Immunity
Supplementary Figure S4. pIRE, pJNK, and CHOP upregulation in lymphoma lines treated with brentuximab vedotin or MMAE
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Brentuximab Vedotin–Driven Microtubule Disruption Results in Endoplasmic Reticulum Stress Leading to Immunogenic Cell Death and Antitumor Immunity
Supplementary Figure S4. pIRE, pJNK, and CHOP upregulation in lymphoma lines treated with brentuximab vedotin or MMAE
- Open Access
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Figure S6 from Brentuximab Vedotin–Driven Microtubule Disruption Results in Endoplasmic Reticulum Stress Leading to Immunogenic Cell Death and Antitumor Immunity
Supplementary Figure S6. Brentuximab vedotin’s multifaceted mechanism of action
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Brentuximab Vedotin–Driven Microtubule Disruption Results in Endoplasmic Reticulum Stress Leading to Immunogenic Cell Death and Antitumor Immunity
Supplementary Figure S6. Brentuximab vedotin’s multifaceted mechanism of action